HK1069413A1 - Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene - Google Patents

Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene

Info

Publication number
HK1069413A1
HK1069413A1 HK05102010.7A HK05102010A HK1069413A1 HK 1069413 A1 HK1069413 A1 HK 1069413A1 HK 05102010 A HK05102010 A HK 05102010A HK 1069413 A1 HK1069413 A1 HK 1069413A1
Authority
HK
Hong Kong
Prior art keywords
polymorphisms
methods
cntf gene
treating psychosis
schizophrenia based
Prior art date
Application number
HK05102010.7A
Other languages
English (en)
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1069413A1 publication Critical patent/HK1069413A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
HK05102010.7A 2001-12-10 2005-03-08 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene HK1069413A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33983501P 2001-12-10 2001-12-10
PCT/EP2002/013937 WO2003054226A2 (fr) 2001-12-10 2002-12-09 Procedes de traitement de psychose et de schizophrenie sur la base de polymorphismes dans le gene cntf

Publications (1)

Publication Number Publication Date
HK1069413A1 true HK1069413A1 (en) 2005-05-20

Family

ID=23330814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102010.7A HK1069413A1 (en) 2001-12-10 2005-03-08 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene

Country Status (16)

Country Link
US (3) US20050059006A1 (fr)
EP (1) EP1458888B1 (fr)
JP (2) JP2005512576A (fr)
CN (1) CN1612941B (fr)
AT (1) ATE503845T1 (fr)
AU (1) AU2002358110A1 (fr)
BR (1) BRPI0214821B8 (fr)
CA (1) CA2468972A1 (fr)
CY (1) CY1111594T1 (fr)
DE (1) DE60239634D1 (fr)
DK (1) DK1458888T3 (fr)
ES (1) ES2364037T3 (fr)
HK (1) HK1069413A1 (fr)
PT (1) PT1458888E (fr)
SI (1) SI1458888T1 (fr)
WO (1) WO2003054226A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214821B8 (pt) 2001-12-10 2021-07-27 Novartis Ag método para determinar a responsividade de indivíduo com distúrbio psicótico ao tratamento com loperidona
JP2008514731A (ja) 2004-09-30 2008-05-08 ヴァンダ ファーマシューティカルズ インコーポレイテッド イロペリドンの投与方法
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
US20080249103A1 (en) * 2006-11-15 2008-10-09 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
WO2008144599A2 (fr) 2007-05-18 2008-11-27 Vanda Pharmaceuticals Inc. Marqueurs génétiques d'efficacité de l'ilopéridone dans le traitement de symptômes psychotiques
US9328387B2 (en) 2007-09-10 2016-05-03 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on SNP genotype
WO2009036100A2 (fr) * 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Prédiction de la prolongation du qt en fonction du génotype snp
CA2709104C (fr) 2007-12-13 2017-06-13 Vanda Pharmaceuticals Inc. Procede et composition pour traiter une affection vehiculee par recepteur de la serotonine
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
EP2570501A3 (fr) * 2008-01-02 2013-04-10 Suregene Llc Marqueurs génétiques de maladie mentale
EP2581453A3 (fr) 2008-01-17 2013-07-10 Suregene Llc Marqueurs génétiques de maladie mentale
CA2742074A1 (fr) * 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Procedes de traitement d'une psychose et de la schizophrenie bases sur des polymorphismes du gene erbb4
JP2012526562A (ja) 2009-05-15 2012-11-01 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療
ES2773711T3 (es) 2012-03-14 2020-07-14 Vanda Pharmaceuticals Inc Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos
US10877498B2 (en) * 2017-10-27 2020-12-29 Brasscraft Manufacturing Company Excess flow and thermal valve
EP3844758A1 (fr) * 2018-08-28 2021-07-07 Koninklijke Philips N.V. Méthode d'évaluation de base d'alignement de génome
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
EP3959340A1 (fr) * 2019-04-24 2022-03-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédé de prédiction de la réponse thérapeutique à des médicaments antipsychotiques
CN110184345B (zh) * 2019-07-11 2020-05-05 南京先声医学检验有限公司 用于检测精神及神经类疾病用药相关snp位点的引物组、应用、产品及方法
CN111187829A (zh) * 2020-02-24 2020-05-22 内蒙古医科大学 Lp基因启动子区甲基化检测引物与检测方法及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4478832A (en) * 1982-06-28 1984-10-23 Chevron Research Company Pesticidal O-(N-alkoxy-substituted-benzimidoyl)-phosphorus esters and thioesters
US5610035A (en) * 1983-12-05 1997-03-11 Institut Pasteur Centre National De La Recherche Scientific Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
EP0359789B1 (fr) 1988-01-21 1993-08-04 Genentech, Inc. Amplification et detection de sequences d'acides nucleiques
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
WO1989010414A1 (fr) 1988-04-28 1989-11-02 Robert Bruce Wallace Polymorphismes (asp) a sequences amplifiees
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
DE68926504T2 (de) 1988-07-20 1996-09-12 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
SG50434A1 (en) 1989-02-13 1998-07-20 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5169766A (en) * 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
EP0534858B2 (fr) * 1991-09-24 2005-04-27 Keygene N.V. Amplification sélective des fragments de restriction: procédé général pour le "fingerprinting" d'ADN
CA2134552A1 (fr) 1992-04-27 1993-11-11 George D. Sorenson Detection de sequences geniques dans des liquides biologiques
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5610053A (en) * 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
WO1995011995A1 (fr) 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
DE69531542T2 (de) * 1994-02-07 2004-06-24 Beckman Coulter, Inc., Fullerton Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
US5578832A (en) * 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5866404A (en) * 1995-12-06 1999-02-02 Yale University Yeast-bacteria shuttle vector
AU710425B2 (en) * 1995-12-18 1999-09-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
CA2268740C (fr) 1996-11-06 2010-07-20 Sequenom, Inc. Immobilisation haute densite d'acides nucleiques
AU746737B2 (en) 1996-11-06 2002-05-02 Sequenom, Inc. Compositions and methods for immobilizing nucleic acids to solid supports
US20040171056A1 (en) * 1999-02-22 2004-09-02 Variagenics, Inc., A Delaware Corporation Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
CA2362533A1 (fr) * 1999-02-22 2000-08-31 Variagenics, Inc. Variations de sequences geniques presentant une utilite pour la selection du traitement d'une maladie
JP2000346828A (ja) * 1999-06-02 2000-12-15 Hitachi Ltd 電気泳動装置
DE1233366T1 (de) 1999-06-25 2003-03-20 Genaissance Pharmaceuticals Verfahren zur herstellung und verwendung von Haplotype Daten
EP1206943B1 (fr) * 1999-08-26 2010-04-07 Takeda Pharmaceutical Company Limited Matrice adherant a la muqueuse nasale
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
JP3324594B2 (ja) * 1999-12-20 2002-09-17 株式会社日立製作所 バイオ製品の品質保証方法及びバイオ情報の配信方法
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
BRPI0214821B8 (pt) * 2001-12-10 2021-07-27 Novartis Ag método para determinar a responsividade de indivíduo com distúrbio psicótico ao tratamento com loperidona
AU2003302442A1 (en) 2002-11-25 2004-06-18 Michael Leslie Harris Multi flush toilet cistern
US7851069B2 (en) 2005-11-18 2010-12-14 Federal Mogul World-Wide, Inc. Heat shield with integral attachment flanges

Also Published As

Publication number Publication date
US8460867B2 (en) 2013-06-11
US20080027106A1 (en) 2008-01-31
AU2002358110A8 (en) 2003-07-09
BRPI0214821B1 (pt) 2015-07-07
AU2002358110A1 (en) 2003-07-09
DE60239634D1 (de) 2011-05-12
PT1458888E (pt) 2011-06-01
CY1111594T1 (el) 2015-10-07
CA2468972A1 (fr) 2003-07-03
ES2364037T3 (es) 2011-08-23
BRPI0214821B8 (pt) 2021-07-27
WO2003054226A3 (fr) 2004-04-01
EP1458888B1 (fr) 2011-03-30
US20050059006A1 (en) 2005-03-17
JP2011006422A (ja) 2011-01-13
CN1612941A (zh) 2005-05-04
CN1612941B (zh) 2011-11-16
US20090239908A1 (en) 2009-09-24
EP1458888A2 (fr) 2004-09-22
SI1458888T1 (sl) 2011-07-29
BR0214821A (pt) 2004-11-03
JP2005512576A (ja) 2005-05-12
JP5785697B2 (ja) 2015-09-30
WO2003054226A2 (fr) 2003-07-03
ATE503845T1 (de) 2011-04-15
DK1458888T3 (da) 2011-06-20

Similar Documents

Publication Publication Date Title
HK1069413A1 (en) Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene
BG66289B1 (en) Combination of epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
PT1572095E (pt) Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
SE9900100D0 (sv) New compounds
HK1016893A1 (en) Agent for treating neurodegenerative disorders
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003038123A3 (fr) Procede de traitement du diabete et conditions apparentees basees sur des polymorphismes dans le gene tcf1
HK1023293A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
AU2002308778A1 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
PL371464A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
WO2002102297A3 (fr) Utilisation d'inhibiteurs de cyclo-oxygenase-2 pour le traitement de la schizophrenie, de troubles delirants, de troubles affectifs, de l'autisme ou de tics
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
HK1080408B (zh) 溴莫尼定在治療痴呆和帕金森病中的用途
HK1040908A1 (en) Use of optically pure (R)-tofisopam for treating and preventing anxiety disorders.
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2002364945A8 (en) Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
EP1374351A4 (fr) Tige filetee pour electrodes en carbone
MXPA04001309A (es) Uso de sps o mch-r para identificar desordenes geneticos al mantener el peso corporal normal.
HUP0202416A3 (en) Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders
FR2826376B1 (fr) Procede de cementation et de carbonitruration des aciers par l'oxyde de carbone
AU2003298547A8 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
MXPA04001001A (es) PRAMIPEXOL PARA EL TRATAMIENTO DEL TRASTORNO DE HIPERACTIVIDAD Y DeFICIT DE LA ATENCION.
ES2193824A1 (es) Nuevos polimorfismos de una sola base (snp) en el gen del retinoblastoma (rb1).

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221208